Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 10;10(2):457-467.
doi: 10.1016/j.gendis.2021.12.007. eCollection 2023 Mar.

Sterol carrier protein 2: A promising target in the pathogenesis of atherosclerosis

Affiliations
Review

Sterol carrier protein 2: A promising target in the pathogenesis of atherosclerosis

Can Xu et al. Genes Dis. .

Abstract

Atherosclerosis, the underlying pathophysiological basis of cardiovascular disease, has been recognized as a lipid-driven chronic inflammatory disease. Sterol carrier protein 2 (SCP-2) is a 13-kDa non-specific lipid-transfer protein expressed by various tissues and cells, such as liver, heart, vascular smooth muscle cells (VSMCs), and macrophages. SCP-2 has an extensive role in cardiovascular and metabolic diseases. Recently, SCP-2 was reported to promote the development of atherosclerosis by regulating lipid metabolism and peroxidation, endocannabinoid metabolism, vascular inflammation, and fatty acid metabolism. In this review, we summarized the recent advances regarding the role of SCP-2 in the pathogenesis of atherosclerosis and tried to provide a rationale for future investigation and a better understanding of the biological functions of SCP-2 in atherosclerotic cardiovascular disease.

Keywords: Atherosclerosis; Fatty acid metabolism; Lipid metabolism; SCP-2; Vascular inflammation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
SCP-2-mediated regulation and the major cardiometabolic risk factors of atherosclerosis. Abbreviations: ACAT1, acyl-CoA: cholesterol acyltransferase 1; SR-A, scavenger receptor class A; ABCA/G1, ATP binding cassette transporter A/G1; NPC1L1, Niemann-Pick C1-like 1; TICE, transintestinal cholesterol efflux; LDLR, low-density lipoprotein receptor; PLOOH, phospholipid hydroperoxide; AEA, N-arachidonoylethanolamine; ChOOH, Cholesterol hydroperoxide; 2-AG, 2-arachinoylglicerol; CB1/2, cannabinoid receptor 1/2; AS, atherosclerosis. Arrows in red: promote; text in red: proatherogenic changes; text in green: antiatherogenic changes; text in black word: un-certain effects.
Figure 2
Figure 2
The SCP-x/pro-SCP-2 gene encodes two 13-kDa SCP-2 precursors. The 13-kDa SCP-2 gene can be produced by two sites. One site codes for a precursor 15-kDa pro-SCP-2 protein that undergoes completely post-translationally cleaved to the mature 13-kDa SCP-2 and a 2-kDa peptide. Another site codes for a full-length 58-kDa SCP-x protein, which is partially post-translationally processed into yield a 46-kDa protein and a 13-kDa SCP-2 protein.

Similar articles

Cited by

References

    1. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659–1724. - PMC - PubMed
    1. Allen N.B., Krefman A.E., Labarthe D., et al. Cardiovascular health trajectories from childhood through middle age and their association with subclinical atherosclerosis. JAMA Cardiol. 2020;5(5):557–566. - PMC - PubMed
    1. Scannapieco F.A., Bush R.B., Paju S. Associations between periodontal disease and risk for atherosclerosis, cardiovascular disease, and stroke. A systematic review. Ann Periodontol. 2003;8(1):38–53. - PubMed
    1. Anand S.S., Yusuf S., Vuksan V., et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE) Lancet. 2000;356(9226):279–284. - PubMed
    1. Maguire E.M., Pearce S.W.A., Xiao Q. Foam cell formation: a new target for fighting atherosclerosis and cardiovascular disease. Vasc Pharmacol. 2019;112:54–71. - PubMed

LinkOut - more resources